Kardigan Inc (KARD) Stock Forecast & Price Target

Kardigan is compelling because it combines an experienced MyoKardia-derived leadership team with three in-licensed, late-stage cardiovascular assets aimed at large, underserved markets with no approved disease-modifying therapies. Its programs already show encouraging human proof-of-concept: danicamtiv improved LVEF by 8.8% in MYH7, 5.9% in TTN, and 7.3% combined sarcomeric cohorts, ataciguat reduced aortic valve calcium accumulation by about 70% versus placebo, and tonlamarsen cut AGT by 67% with repeat dosing and reduced systolic BP surges by 28%. With all three readouts expected in 1H27 and a capital-efficient history of acquiring Phase 2b-or-later assets for roughly $64 million upfront, the company has multiple near-term catalysts and an asymmetric fundamental setup.

Kardigan is negatively viewed because its lead tonlamarsen program failed the KARDINAL BP co-primary endpoint, and the reported benefit relied on pooled-arm and subgroup effects rather than a clean placebo-controlled separation, which weakens confidence in the asset’s true efficacy. The safety profile is not catastrophic, but the signal is still mixed, with more TEAEs and SAEs on continued monthly dosing, more injection-site reactions, and a fatal renal failure case that underscores concerns in a program built around renal differentiation. As a clinical-stage company with no commercial revenue, Kardigan remains highly dependent on three Phase 2b assets, faces meaningful regulatory and commercialization risk, and will likely need substantial additional funding despite approximately $661M of cash as of 2Q26 and runway into 2028.